DocumentRX-1170
Issued
Read3 min

Alcohol Cuts Anti-PD-1 Efficacy Roughly 50% in Mouse Cancer Models

UNC Chapel Hill data in Science Signaling show ethanol cut anti-PD-1 response about 50% in mice; patients drinking eight-plus drinks weekly had poorer ICI survival. TIGIT blockade rescued efficacy.

TAG K-9861 · 505 words on the filing

Alcohol Suppresses Some T Cells, Boosts Others, Blunting Anti-PD-1 Response in Mice
Alcohol Suppresses Some T Cells, Boosts Others, Blunting Anti-PD-1 Response in MiceDarkoStojanovic / pixabay

Summary of findings

  • Ethanol reduced anti-PD-1 efficacy by roughly 50% in mouse lung and bladder cancer models.
  • Up to 76.4% of cancer patients still drink alcohol, per studies cited in the paper.
  • Patients self-reporting eight or more drinks per week showed poorer survival on checkpoint inhibitors.
  • Anti-TIGIT antibodies fully restored anti-PD-1 efficacy in mice; betulin partially improved it.
  • The paper was published in Science Signaling by Kristen Gilley and colleagues at UNC Chapel Hill.

Moderate-to-heavy ethanol exposure cut anti-PD-1 efficacy by roughly 50% in mouse models of lung and bladder cancer, according to University of North Carolina at Chapel Hill researchers writing in Science Signaling. Tumor recurrence rose in parallel. The paper, led by Kristen Gilley, is titled "Alcohol use reduces the efficacy of anti-PD1 immunotherapy by disrupting antitumor immunity."

The clinical stakes are broad. Recent studies cited by the authors put alcohol use among cancer patients at up to 76.4%, while medical societies have called for research on how drinking affects treatment outcomes. Complete responses to immune checkpoint inhibition remain rare in advanced disease, and alcohol is known to impair adaptive immunity.

What did the mouse experiments show?

The team dosed lung and bladder cancer models with ethanol alongside anti-PD-1 antibodies. Both models lost about half their treatment benefit. The mechanism work centered on MB49 bladder tumors.

  • Tumor-infiltrating T cell numbers fell.
  • Tumor-associated CD4+ T cells shifted from a T helper 1 profile toward T helper 17.
  • Tissue-resident memory T cells declined.
  • The proportion of T cells expressing TIGIT, an alternative checkpoint receptor, rose.
  • Ethanol induced SREBP-mediated lipid signaling in tumor-associated T cells.

Each shift points to a druggable axis rather than a generalized toxicity.

Can the losses be reversed?

Partly. TIGIT blockade with antibodies restored anti-PD-1 efficacy in the treated animals. Inhibiting SREBP signaling with betulin improved efficacy to a lesser extent. The two rescue strategies map directly onto the two mechanisms the authors identified: alternative checkpoint upregulation and altered lipid metabolism in tumor-associated T cells.

The mouse data are mechanistic, not a dosing recommendation. Takeaway: two distinct interventions recovered checkpoint-inhibitor benefit in vivo.

What did the patient cohort show?

The researchers retrospectively analyzed patients with skin, lung, bladder, or head and neck cancer treated with immune checkpoint inhibitors. Patients reporting eight or more drinks per week showed poorer survival after starting treatment. In lung cancer specifically, regular alcohol use associated with a reduced survival benefit from checkpoint inhibition.

The other tumor types yielded less definitive results. Self-reported alcohol use was too limited in those groups to support firm conclusions, the authors noted. Eight drinks a week is the operating threshold — roughly one drink per day.

Where does the work go next?

"This work is an initial resource toward establishing the risk of regular alcohol use on the efficacy of [immune checkpoint inhibition] and identifying the mechanisms that might be targeted for intervention," Gilley et al. wrote.

The authors call for incorporating patient alcohol use into cancer databases. That would let researchers quantify drinking effects across modalities — CAR T cell therapy, chemotherapy, and radiation — and across multiple cancer types. The current findings rest on mouse models plus one retrospective cohort; prospective confirmation and trial-level alcohol capture remain outstanding.

For pipeline teams, the immediate relevance is trial design. Alcohol exposure is rarely stratified in checkpoint-inhibitor studies, and the UNC data suggest it can halve response in preclinical models.

via science.org (Original)

Share this article:

More from Grace Kim

Grace Kim

Show full bio

Market editor covering companies, deals and strategy in global pharmaceutical industry at PharmInsider.

7 articles

Linked filings

  1. E-3628
  2. V-7932
  3. V-1848
  4. P-9899
  5. C-7994

« Previous filing